Real-World Outcomes of Nivolumab and Cabozantinib in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium
Abstract
Share and Cite
Stukalin, I.; Wells, J.C.; Graham, J.; Yuasa, T.; Beuselinck, B.; Kollmansberger, C.; Ernst, D.S.; Agarwal, N.; Le, T.; Donskov, F.; et al. Real-World Outcomes of Nivolumab and Cabozantinib in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Curr. Oncol. 2019, 26, 175-179. https://doi.org/10.3747/co.26.4595
Stukalin I, Wells JC, Graham J, Yuasa T, Beuselinck B, Kollmansberger C, Ernst DS, Agarwal N, Le T, Donskov F, et al. Real-World Outcomes of Nivolumab and Cabozantinib in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Current Oncology. 2019; 26(2):175-179. https://doi.org/10.3747/co.26.4595
Chicago/Turabian StyleStukalin, I., J.C. Wells, J. Graham, T. Yuasa, B. Beuselinck, C. Kollmansberger, D.S. Ernst, N. Agarwal, T. Le, F. Donskov, and et al. 2019. "Real-World Outcomes of Nivolumab and Cabozantinib in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium" Current Oncology 26, no. 2: 175-179. https://doi.org/10.3747/co.26.4595